Drug Repurposing for Parkinson's Disease Using Random Walk With Restart Algorithm and the Parkinson's Disease Ontology Database
0
🔍
Sign in to get full access
Overview
- Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain.
- Current therapies can only help manage Parkinson's symptoms, but a cure remains elusive.
- Drug repurposing, the process of finding new uses for existing drugs, is an efficient way to develop new treatments.
- This research presents a novel computational platform that integrates gene expression data, biological networks, and a Parkinson's drug database to identify potential drug repurposing candidates.
Plain English Explanation
Parkinson's disease is a condition where certain brain cells that produce a chemical called dopamine slowly die off. Dopamine is important for controlling movement, so as these cells are lost, people with Parkinson's experience symptoms like tremors, stiffness, and difficulty moving.
Unfortunately, there is no cure for Parkinson's yet. The available treatments can only help manage the symptoms for a time, but don't stop the underlying disease progression.
One promising approach is drug repurposing, which means finding new uses for existing medications. This can be faster and cheaper than developing completely new drugs from scratch.
In this study, the researchers developed a computer program that combines several different types of data - gene expression, biological networks, and a Parkinson's drug database. By analyzing this information together, the program can identify existing drugs that might be repurposed to treat Parkinson's.
The researchers used machine learning techniques to rank and prioritize the potential drug candidates based on how well they might work. Their results highlight several promising therapies that could be studied further for Parkinson's treatment.
Technical Explanation
The researchers designed a novel computational platform that integrates three key components: gene expression data, biological networks, and the Parkinson's Disease Ontology Database (PDOD).
First, they used gene expression analysis to identify genes and pathways associated with Parkinson's disease. This provided insights into the underlying biological mechanisms involved.
Next, they leveraged biological network analysis, specifically the Random Walk with Restart (RWR) algorithm, to prioritize genes and proteins based on their connection to the Parkinson's-related genes.
Finally, they combined this network prioritization with data from the PDOD to score potential drug candidates based on their predicted efficacy for Parkinson's treatment. This PDOD scoring system allowed them to rank and select the most promising drug repurposing opportunities.
Overall, this integrated approach of gene expression analysis, network prioritization, and drug target data evaluation enabled a comprehensive evaluation of drug repurposing potential for Parkinson's disease.
Critical Analysis
The researchers acknowledge several limitations in their work. For example, the gene expression data and biological network models used may not fully capture the complex pathogenesis of Parkinson's disease. Additionally, the PDOD database, while extensive, may still be incomplete or biased.
Further research is needed to validate the promising drug candidates identified in this study through in vitro and in vivo experiments. The computational predictions should be carefully tested and confirmed before advancing any repurposed drugs to clinical trials.
It is also worth noting that drug repurposing, while potentially faster than developing new drugs from scratch, still faces challenges in terms of regulatory approval and commercialization. The researchers do not address these practical barriers in detail.
Overall, this research provides a valuable computational framework for identifying drug repurposing opportunities, but the findings should be interpreted with appropriate caution and further validated through additional studies.
Conclusion
This study presents a novel computational platform that leverages gene expression data, biological networks, and Parkinson's drug databases to systematically identify existing medications that could be repurposed to treat Parkinson's disease.
The researchers' approach of integrating multiple data sources and using advanced machine learning techniques is a promising step towards accelerating the development of new Parkinson's therapies. The highlighted drug candidates warrant further investigation through experimental validation and clinical studies.
If successful, drug repurposing efforts like this could potentially lead to new treatment options for Parkinson's patients, offering hope in the ongoing search for a cure or more effective management of this debilitating neurodegenerative disorder.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
🔍
0
Drug Repurposing for Parkinson's Disease Using Random Walk With Restart Algorithm and the Parkinson's Disease Ontology Database
Pratham Kankariya, Rachita Rode, Kevin Mudaliar, Prof. Pranali Hatode
Parkinson's disease is a progressive and slowly developing neurodegenerative disease, characterized by dopaminergic neuron loss in the substantia nigra region of the brain. Despite extensive research by scientists, there is not yet a cure to this problem and the available therapies mainly help to reduce some of the Parkinson's symptoms. Drug repurposing (that is, the process of finding new uses for existing drugs) receives more appraisals as an efficient way that allows for reducing the time, resources, and risks associated with the development of new drugs. In this research, we design a novel computational platform that integrates gene expression data, biological networks, and the PDOD database to identify possible drug-repositioning agents for PD therapy. By using machine learning approaches like the RWR algorithm and PDOD scoring system we arrange drug-disease conversions and sort our potential sandboxes according to their possible efficacy. We propose gene expression analysis, network prioritization, and drug target data analysis to arrive at a comprehensive evaluation of drug repurposing chances. Our study results highlight such therapies as promising drug candidates to conduct further research on PD treatment. We also provide the rationale for promising drug repurposing ideas by using various sources of data and computational approaches.
Read more4/16/2024
🗣️
0
Learning a Patent-Informed Biomedical Knowledge Graph Reveals Technological Potential of Drug Repositioning Candidates
Yongseung Jegal, Jaewoong Choi, Jiho Lee, Ki-Su Park, Seyoung Lee, Janghyeok Yoon
Drug repositioning-a promising strategy for discovering new therapeutic uses for existing drugs-has been increasingly explored in the computational science literature using biomedical databases. However, the technological potential of drug repositioning candidates has often been overlooked. This study presents a novel protocol to comprehensively analyse various sources such as pharmaceutical patents and biomedical databases, and identify drug repositioning candidates with both technological potential and scientific evidence. To this end, first, we constructed a scientific biomedical knowledge graph (s-BKG) comprising relationships between drugs, diseases, and genes derived from biomedical databases. Our protocol involves identifying drugs that exhibit limited association with the target disease but are closely located in the s-BKG, as potential drug candidates. We constructed a patent-informed biomedical knowledge graph (p-BKG) by adding pharmaceutical patent information. Finally, we developed a graph embedding protocol to ascertain the structure of the p-BKG, thereby calculating the relevance scores of those candidates with target disease-related patents to evaluate their technological potential. Our case study on Alzheimer's disease demonstrates its efficacy and feasibility, while the quantitative outcomes and systematic methods are expected to bridge the gap between computational discoveries and successful market applications in drug repositioning research.
Read more7/25/2024
0
DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning
Yoshitaka Inoue, Tianci Song, Tianfan Fu
Drug repurposing offers a promising avenue for accelerating drug development by identifying new therapeutic potentials of existing drugs. In this paper, we propose a multi-agent framework to enhance the drug repurposing process using state-of-the-art machine learning techniques and knowledge integration. Our framework comprises several specialized agents: an AI Agent trains robust drug-target interaction (DTI) models; a Knowledge Graph Agent utilizes the drug-gene interaction database (DGIdb), DrugBank, Comparative Toxicogenomics Database (CTD), and Search Tool for Interactions of Chemicals (STITCH) to systematically extract DTIs; and a Search Agent interacts with biomedical literature to annotate and verify computational predictions. By integrating outputs from these agents, our system effectively harnesses diverse data sources, including external databases, to propose viable repurposing candidates. Preliminary results demonstrate the potential of our approach in not only predicting drug-disease interactions but also in reducing the time and cost associated with traditional drug discovery methods. This paper highlights the scalability of multi-agent systems in biomedical research and their role in driving innovation in drug repurposing. Our approach not only outperforms existing methods in predicting drug repurposing potential but also provides interpretable results, paving the way for more efficient and cost-effective drug discovery processes.
Read more9/14/2024
0
Accelerating Complex Disease Treatment through Network Medicine and GenAI: A Case Study on Drug Repurposing for Breast Cancer
Ahmed Abdeen Hamed, Tamer E. Fandy
The objective of this research is to introduce a network specialized in predicting drugs that can be repurposed by investigating real-world evidence sources, such as clinical trials and biomedical literature. Specifically, it aims to generate drug combination therapies for complex diseases (e.g., cancer, Alzheimer's). We present a multilayered network medicine approach, empowered by a highly configured ChatGPT prompt engineering system, which is constructed on the fly to extract drug mentions in clinical trials. Additionally, we introduce a novel algorithm that connects real-world evidence with disease-specific signaling pathways (e.g., KEGG database). This sheds light on the repurposability of drugs if they are found to bind with one or more protein constituents of a signaling pathway. To demonstrate, we instantiated the framework for breast cancer and found that, out of 46 breast cancer signaling pathways, the framework identified 38 pathways that were covered by at least two drugs. This evidence signals the potential for combining those drugs. Specifically, the most covered signaling pathway, ID hsa:2064, was covered by 108 drugs, some of which can be combined. Conversely, the signaling pathway ID hsa:1499 was covered by only two drugs, indicating a significant gap for further research. Our network medicine framework, empowered by GenAI, shows promise in identifying drug combinations with a high degree of specificity, knowing the exact signaling pathways and proteins that serve as targets. It is noteworthy that ChatGPT successfully accelerated the process of identifying drug mentions in clinical trials, though further investigations are required to determine the relationships among the drug mentions.
Read more6/28/2024